The COVID-19 Pandemic and Cancer Screening Deficits in the United States
A retrospective cohort study quantified cancer screening deficits in the U.S. associated with the COVID-19 pandemic and identified differences according to region and socioeconomic status...
Oncologists’ Views on Challenges in Opioid Prescribing for Patients With Cancer-Related Pain
An interview study identified challenges and measures for improvement cited by oncologists in the safe and effective prescribing of opioids for their patients with cancer-related pain...
Diagnosis-to-Treatment Interval and Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
A study found that a short diagnosis-to-treatment interval in patients with DLBCL was associated with higher baseline tumor burden, reflected in higher pretreatment ctDNA levels...
Expert Panel–Endorsed Quality Measures for End-of-Life Care for Children With Cancer
There is currently no consensus on what quality end-of-life care for children with cancer looks like, or how to measure and deliver it; however...
ASCO Coronavirus Resources
As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...
Jame Abraham: Breast Cancer Screening With Clinical Breast Examination in Low- and Middle-Income Countries
Matthew Zibelman: Pembrolizumab in First-Line Treatment of Metastatic Clear Cell and Non–Clear Cell RCC
Nancy E. Davidson on Cancer and COVID-19: Reflections at 1 Year
Nadine M. Tung on Breast Cancer Susceptibility Genes: Putting the Pieces Together
Chandrakanth Are on the Physician-Patient Relationship
Sponsored Content
Sponsored by Puma Biotechnology
Adjuvant Therapy in HER2-Positive, Hormone Receptor–Positive Breast Cancer
FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma
On April 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta), a CD19-directed antibody and alkylating agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, ...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Shannon N. Westin, MD, on Treating Endometrial Cancer With Enzalutamide, Paclitaxel, and Carboplatin
Five-Year Efficacy Outcomes With Pembrolizumab vs Chemotherapy in Metastatic NSCLC With PD-L1 Tumor Proportion Score of at Least 50%
As reported by Martin Reck, MD, PhD, and colleagues in the Journal of Clinical Oncology, the 5-year follow-up of the pivotal phase III KEYNOTE-024 trial shows maintained overall survival benefit in patients treated with pembrolizumab vs chemotherapy—despite substantial crossover to the...
Diagnosis-to-Treatment Interval and Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
In a study reported in the Journal of Clinical Oncology, Stefan Alig, MD, and colleagues found that a short diagnosis-to-treatment interval in patients with diffuse large B-cell lymphoma (DLBCL) was associated with higher baseline tumor burden, reflected in higher pretreatment circulating tumor DNA ...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Effect of Oral Chemotherapy Management Program on Capecitabine Toxicity
In a health system retrospective study reported in JCO Oncology Practice, Nhean et al found that implementation of an oral chemotherapy management program was associated with reduced rates of any-grade and severe capecitabine toxicity, less frequent toxicity-related emergency department visits and...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
